Table 6: rSBA-MenA, rSBA-MenC, rSBA-MenW-135, and rSBA-MenY antibody response one month after MenACWY-TT vaccination in children and adolescents (ATP immunogenicity cohort).

ReferenceAge groupVaccine 𝑁 VRR[95% CI] 𝑁 GMT[95% CI]

rSBA-MenA

Østergaard et al., 2009 [86]15–19 yearsMenACWY-TT2387.0[66.4–97.2]249264[6342–13532]
ACWY-PS2378.3[56.3–92.5]258284[6035–11370]
Knuf et al., 2010 [87]3–5 yearsMenACWY-TT4092.5[79.6–98.4]498299.4[6734.2–10228.4]
ACWY-PS3180.6[62.5–92.5]333798.4[2888.9–4994.2]
Bermal et al., 2011 [88]11–17 yearsMenACWY-TT61585.4[82.3–88.1]7526106.8[5739.5–6497.6]
ACWY-PS21579.5[73.5–84.7]2523203.0[2854.1–3594.6]

rSBA-MenC

Østergaard et al., 2009 [86]15–19 yearsMenACWY-TT2495.8[78.9–99.9]244329[2404–7795]
ACWY-PS2491.7[73.0–99.0]251567[757–3245]
Knuf et al., 2010 [87]3–5 yearsMenACWY-TT4793.6[82.5–98.7]491577.8[1123.5–2215.9]
ACWY-PS3281.3[63.6–92.8]34445.4[263.3–753.3]
Bermal et al., 2011 [88]11–17 yearsMenACWY-TT71997.1[95.6–98.2]75412645.5[11531.8–13866.7]
ACWY-PS23796.6[93.5–98.5]2528271.6[6937.3–9862.4]

rSBA-MenW-135

Østergaard et al., 2009 [86]15–19 yearsMenACWY-TT2391.3[72.0–98.9]244422[2939–6653]
ACWY-PS2596.0[79.6–99.9]253486[2447–4967]
Knuf et al., 2010 [87]3–5 yearsMenACWY-TT47100[92.5–100]495987.2[4846.9–7395.7]
ACWY-PS3296.9[83.8–99.9]341811.1[1233.3–2659.5]
Bermal et al., 2011 [88]11–17 yearsMenACWY-TT71796.5[94.9–97.7]7598390.1[7777.8–9050.7]
CWY-PS24288.0[83.2–91.8]2522679.3[2363.7–3037.2]

rSBA-MenY

Østergaard et al., 2009 [86]15–19 yearsMenACWY-TT2479.2[57.8–92.9]242756[2023–3755]
ACWY-PS2588.0[68.8–97.5]253056[1892–4937]
Knuf et al., 2010 [87]3–5 yearsMenACWY-TT48100[92.6–100]496433.0[4921.0–8409.6]
ACWY-PS3479.4[62.1–91.3]341435.5[972.6–2118.7]
Bermal et al., 2011 [88]11–17 yearsMenACWY-TT73793.1[91.0–94.8]75813865.2[12968.1–14824.4]
ACWY-PS24678.0[72.3–83.1]2525245.3[4644.2–5924.1]

𝑁 : numbers of subjects with available data, 95% CI: 95% confidence interval, GMT: geometric mean titre, VRR: vaccine response rate, Vaccine response defined as: (1) for initially seronegative subjects, antibody titres ≥1 : 32 at one month after vaccination, (2) for initially seropositive subjects, antibody titres at one month after vaccination ≥4-fold the pre-vaccination antibody titre, Results of this table were previously published [8688].